Evaluation of safety following Immune Tolerance Induction treatment with turoctocog alfa in patients with haemophilia A following inhibitor development in NN7170-4213 trial
Latest Information Update: 04 Jan 2022
At a glance
- Drugs Turoctocog alfa (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 10 Oct 2020 This trial has been completed in United Kingdom and Germany [Date of the global end of the trial: 19 June 2019].
- 02 Jul 2020 Status changed from completed to discontinued.
- 02 Jul 2019 Status changed from active, no longer recruiting to completed.